Alexander J Millman1, Noele P Nelson1, Claudia Vellozzi1. 1. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
PURPOSE OF REVIEW: This review highlights key studies and recently published data, policies, and recommendations related to hepatitis C virus (HCV) epidemiology, transmission, and treatment. RECENT FINDINGS: HCV is a leading cause of liver-related deaths, cirrhosis, and hepatocellular carcinoma. Since 2011 and accelerating since 2013, new, safe, tolerable, and curative therapies have considerably altered clinical and public health frameworks related to the prevention, control and clinical management of HCV. Nevertheless, there are several populations in the United States that are important to consider because of disparities in HCV prevalence and transmission risk. Adults born during 1945-1965 have an estimated anti-HCV antibody prevalence of ~3%, which is six times higher than among other adults, are often unaware of their infections, and are at increased risk of having HCV-associated morbidity and mortality from decades of chronic infection. Since the early 2000s, increasing incidence of acute HCV infections among young, white, non-urban people who inject drugs have been reported. Despite promising therapeutic advances, significant challenges remain for reducing HCV-associated morbidity and mortality. SUMMARY: The high burden of HCV and significant health consequences associated with chronic infection make HCV a critical public health priority. Advances in HCV treatment have created new opportunities for reducing HCV-associated morbidity and mortality. These treatments are safe, well-tolerated, and highly effective; however, benefits cannot be realized without a significant increase in the number of persons tested for HCV so that all chronically infected individuals can be aware of their diagnosis and linked to appropriate clinical care.
PURPOSE OF REVIEW: This review highlights key studies and recently published data, policies, and recommendations related to hepatitis C virus (HCV) epidemiology, transmission, and treatment. RECENT FINDINGS:HCV is a leading cause of liver-related deaths, cirrhosis, and hepatocellular carcinoma. Since 2011 and accelerating since 2013, new, safe, tolerable, and curative therapies have considerably altered clinical and public health frameworks related to the prevention, control and clinical management of HCV. Nevertheless, there are several populations in the United States that are important to consider because of disparities in HCV prevalence and transmission risk. Adults born during 1945-1965 have an estimated anti-HCV antibody prevalence of ~3%, which is six times higher than among other adults, are often unaware of their infections, and are at increased risk of having HCV-associated morbidity and mortality from decades of chronic infection. Since the early 2000s, increasing incidence of acute HCV infections among young, white, non-urban people who inject drugs have been reported. Despite promising therapeutic advances, significant challenges remain for reducing HCV-associated morbidity and mortality. SUMMARY: The high burden of HCV and significant health consequences associated with chronic infection make HCV a critical public health priority. Advances in HCV treatment have created new opportunities for reducing HCV-associated morbidity and mortality. These treatments are safe, well-tolerated, and highly effective; however, benefits cannot be realized without a significant increase in the number of persons tested for HCV so that all chronically infected individuals can be aware of their diagnosis and linked to appropriate clinical care.
Entities:
Keywords:
Baby Boomer; Direct Acting Antiviral; Hepatitis C; Injection Drug Use
Authors: Jorge Mera; Claudia Vellozzi; Susan Hariri; Hélène Carabin; Douglas A Drevets; Anna Miller; Brigg Reilley; Whitney Essex; David Gahn; Lisa Lyons; Jessica Leston; John W Ward Journal: MMWR Morb Mortal Wkly Rep Date: 2016-05-13 Impact factor: 17.586
Authors: Amanda Weir; Allan McLeod; Hamish Innes; Heather Valerio; Esther J Aspinall; David J Goldberg; Stephen T Barclay; John F Dillon; Ray Fox; Andrew Fraser; Peter C Hayes; Nicholas Kennedy; Peter R Mills; Adrian J Stanley; Celia Aitken; Rory Gunson; Kate Templeton; Alison Hunt; Paul McIntyre; Sharon J Hutchinson Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492
Authors: J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht Journal: N Engl J Med Date: 1998-11-19 Impact factor: 91.245
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal Journal: J Hepatol Date: 2016-01-30 Impact factor: 30.083
Authors: Biao Zhou; Gao Feng Feng Cai; Hua Kun Kun Lv; Shuang Fei Fei Xu; Zheng Ting Ting Wang; Zheng Gang Gang Jiang; Chong Gao Gao Hu; Yong Di Di Chen Journal: Int J Environ Res Public Health Date: 2019-07-02 Impact factor: 3.390
Authors: Anca Elena Butaru; Mădălin Mămuleanu; Costin Teodor Streba; Irina Paula Doica; Mihai Mircea Diculescu; Dan Ionuț Gheonea; Carmen Nicoleta Oancea Journal: Diagnostics (Basel) Date: 2022-01-29
Authors: J E Sherbuk; K A McManus; E T Rogawski McQuade; T Knick; Z Henry; R Dillingham Journal: Open Forum Infect Dis Date: 2018-09-20 Impact factor: 3.835